Meeting
2013 Genitourinary Cancers Symposium
Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma.
Authors
Robert John Motzer
Memorial Sloan-Kettering Cancer Center, New York, NY
Robert John Motzer , Timothy Eisen , Thomas E. Hutson , Cezary Szczylik , Mizue Krygowski , Andrew Louis Strahs , Brooke Esteves , Andrew P. Krivoshik , Anna Berkenblit , Dmitry Nosov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01030783
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 350)
DOI
10.1200/jco.2013.31.6_suppl.350
Abstract #
350
Poster Bd #
B3
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
First Author: Brian I. Rini
Poster
2015 ASCO Annual Meeting
Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902).
First Author: Thomas Hutson
Poster
2013 Genitourinary Cancers Symposium
Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib.
First Author: Robert John Motzer
Poster
2013 Genitourinary Cancers Symposium
Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).
First Author: Thomas E. Hutson